Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Coya Therapeutics, Inc.NASDAQ: COYA
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 40.2% from a year ago
Common stock stood at $2.35K at the end of Q1 FY2026, up 40.2% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at +100.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +40.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 2.09K USD
- Year-over-year change
- +25.3%
- 4-year CAGR
- +68.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.09K | +25.3% |
| FY2024 | 2024-12-31 | 1.67K | +16.0% |
| FY2023 | 2023-12-31 | 1.44K | +456.4% |
| FY2022 | 2022-12-31 | 259 | +0.0% |
| FY2021 | 2021-12-31 | 259 | — |
Common Stock vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's Mar 2026 common stock of $2.35K is the lowest of the 11 companies compared; the peer median is $81.44K.
- Its year-over-year change of +40.2% is the 4th highest of 11, against a peer median of +1.6%.
- Common stock amounts to 0.0% of total assets for COYA, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12.01M | +1200500.0% | -47.7% | 55.4% | |
| Mar 2026 | $636K | +0.8% | +0.9% | 0.3% | |
| Mar 2026 | $491K | +0.0% | -0.3% | 0.2% | |
| Mar 2026 | $167K | +135.2% | +22.6% | 0.1% | |
| Mar 2026 | $91.88K | +2.4% | +79.2% | 0.2% | |
| Mar 2026 | $71K | -1.4% | +5.4% | 0.0% | |
| Mar 2026 | $7K | +40.0% | +11.9% | 0.0% | |
| Mar 2026 | $6K | +0.0% | +6.3% | 0.0% | |
| Mar 2026 | $5.31K | +90.0% | +56.0% | 0.0% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $4K | +0.0% | +26.0% | 0.0% |
| Mar 2026 | $2.35K | +40.2% | +100.7% | 0.0% | |
| Peer median (excluding COYA) | $81.44K | +1.6% | +9.1% | 0.1% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 5.93M | 32.63M | 38.34M | 46.82M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 7.5M | 730.58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 4.58M | 7.18M | 41.2M | 44.31M | 49.94M |
| Property, Plant & Equipment (Net) | 120.67K | 93.31K | 65.95K | 38.59K | 11.23K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87.18K | 1.12M | 0 | 0 | 0 |
| Total Non-current Assets | 207.85K | 1.21M | 65.95K | 38.59K | 11.23K |
| Total Assets | 4.79M | 8.4M | 41.26M | 44.35M | 49.95M |
| Account Payables | 857.57K | 1.82M | 1.16M | 1.59M | 1.06M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 723.85K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 923.11K | 848.29K | 1.2M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.15M | 3.82M | 5.05M | 3.82M | 5.87M |
| Long-term Debt | 0 | 12.97M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 574.69K | 945.45K | 1.05M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 12.97M | 574.69K | 945.45K | 1.05M |
| Total Liabilities | 1.15M | 16.79M | 5.63M | 4.77M | 6.92M |
| Common Stock | 259 | 259 | 1.44K | 1.67K | 2.09K |
| Retained Earnings | (5.62M) | (17.87M) | (25.86M) | (40.74M) | (61.96M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (11.25K) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.64M | (8.39M) | 35.64M | 39.58M | 43.03M |
| Total Debt | 0 | 12.97M | 0 | 0 | 0 |
| Net Debt | (4.34M) | 7.03M | (32.63M) | (38.34M) | (46.82M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.